KR20170034439A - 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 - Google Patents

트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 Download PDF

Info

Publication number
KR20170034439A
KR20170034439A KR1020177006662A KR20177006662A KR20170034439A KR 20170034439 A KR20170034439 A KR 20170034439A KR 1020177006662 A KR1020177006662 A KR 1020177006662A KR 20177006662 A KR20177006662 A KR 20177006662A KR 20170034439 A KR20170034439 A KR 20170034439A
Authority
KR
South Korea
Prior art keywords
amine
pyridin
isoxazolo
pyridine
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177006662A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 데즈먼드 팔메
라이 밍 칭
스와나라타 아쿠라티야 가마지
Original Assignee
오클랜드 유니서비시즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오클랜드 유니서비시즈 리미티드 filed Critical 오클랜드 유니서비시즈 리미티드
Priority to KR1020247002643A priority Critical patent/KR102746352B1/ko
Publication of KR20170034439A publication Critical patent/KR20170034439A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177006662A 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 Ceased KR20170034439A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002643A KR102746352B1 (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ628688 2014-08-13
NZ62868814 2014-08-13
PCT/IB2015/056129 WO2016024233A1 (en) 2014-08-13 2015-08-12 Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002643A Division KR102746352B1 (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Publications (1)

Publication Number Publication Date
KR20170034439A true KR20170034439A (ko) 2017-03-28

Family

ID=55303920

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177006662A Ceased KR20170034439A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020247002643A Active KR102746352B1 (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020247042036A Pending KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247002643A Active KR102746352B1 (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
KR1020247042036A Pending KR20250007032A (ko) 2014-08-13 2015-08-12 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도

Country Status (10)

Country Link
US (3) US10888567B2 (enExample)
EP (1) EP3180002B1 (enExample)
JP (2) JP7323985B2 (enExample)
KR (3) KR20170034439A (enExample)
CN (3) CN117618423A (enExample)
AU (2) AU2015302908B2 (enExample)
CA (1) CA2957884A1 (enExample)
ES (1) ES2925471T3 (enExample)
WO (1) WO2016024233A1 (enExample)
ZA (1) ZA201700924B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200130847A (ko) * 2018-03-14 2020-11-20 후아웨이 테크놀러지 컴퍼니 리미티드 데이터 전송 방법, 장치 및 시스템

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170034439A (ko) 2014-08-13 2017-03-28 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
US11414428B2 (en) 2015-08-27 2022-08-16 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
RU2619120C1 (ru) * 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике
EP3269714A1 (en) 2016-07-13 2018-01-17 Netherlands Translational Research Center B.V. Inhibitors of tryptophan 2,3-dioxygenase
CN109952300B (zh) 2016-09-24 2022-01-18 百济神州有限公司 5或8-取代的咪唑并[1,5-a]吡啶
KR20190084053A (ko) 2016-10-13 2019-07-15 주노 쎄러퓨티크스 인코퍼레이티드 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물
EP3570832A4 (en) 2017-01-17 2020-06-10 Board Of Regents, The University Of Texas System NOVEL COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHANE DIOXYGENASE
CN106905256A (zh) * 2017-03-06 2017-06-30 中国药科大学 苯并五元杂环类ido1抑制剂、其制备方法及应用
WO2019076358A1 (en) * 2017-10-19 2019-04-25 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
JP6912016B1 (ja) * 2020-04-10 2021-07-28 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
WO2022184930A2 (en) 2021-03-05 2022-09-09 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
JP2025507981A (ja) 2022-03-04 2025-03-21 アンティド セラピューティクス インターナショナル ソシエテ ア レスポンサビリテ リミティー トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の二重阻害剤と療法におけるそれらの使用
WO2025046519A1 (en) * 2023-08-31 2025-03-06 Antido Therapeutics International Sarl Combination for use in the treatment of glioma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL123588B1 (en) 1979-12-20 1982-10-30 Akad Rolnicza Rotary dynamometer for measurement of useful work of machining
AU2001255410A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
JP2007529468A (ja) 2004-03-16 2007-10-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンズイソオキサゾール
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
AU2006244068B9 (en) * 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
WO2010068453A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
BRPI1009428A2 (pt) 2009-03-10 2016-03-01 Gruenenthal Gmbh 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
BR112012020271A2 (pt) 2010-02-11 2017-08-29 Univ Vanderbilt Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica
US20100234491A1 (en) * 2010-05-27 2010-09-16 Morteza Khorrami Method and material for manufacturing fiber cement board
IN2013CN01335A (enExample) * 2010-07-22 2015-08-07 Basf Se
JP5672077B2 (ja) * 2011-03-04 2015-02-18 セイコーエプソン株式会社 発光素子、発光装置、表示装置および電子機器
IN2014CN04204A (enExample) 2012-01-12 2015-07-17 Basf Se
PL220630B1 (pl) * 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
KR20170034439A (ko) 2014-08-13 2017-03-28 오클랜드 유니서비시즈 리미티드 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
RU2619120C1 (ru) 2016-06-06 2017-05-12 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200130847A (ko) * 2018-03-14 2020-11-20 후아웨이 테크놀러지 컴퍼니 리미티드 데이터 전송 방법, 장치 및 시스템
KR20220127390A (ko) * 2018-03-14 2022-09-19 후아웨이 테크놀러지 컴퍼니 리미티드 데이터 전송 방법, 장치 및 시스템
US11871412B2 (en) 2018-03-14 2024-01-09 Huawei Technologies Co., Ltd. Data transmission method, apparatus, and system
US12418915B2 (en) 2018-03-14 2025-09-16 Huawei Technologies Co., Ltd. Data transmission method, apparatus, and system

Also Published As

Publication number Publication date
KR20240017411A (ko) 2024-02-07
CN117618423A (zh) 2024-03-01
KR20250007032A (ko) 2025-01-13
AU2020203116B2 (en) 2021-10-21
US10888567B2 (en) 2021-01-12
CN106794176A (zh) 2017-05-31
JP2021006579A (ja) 2021-01-21
US11826316B2 (en) 2023-11-28
EP3180002A1 (en) 2017-06-21
CN117599049A (zh) 2024-02-27
WO2016024233A1 (en) 2016-02-18
JP2017527548A (ja) 2017-09-21
AU2020203116A1 (en) 2020-05-28
ZA201700924B (en) 2022-11-30
KR102746352B1 (ko) 2024-12-24
CA2957884A1 (en) 2016-02-18
US20170224701A1 (en) 2017-08-10
AU2015302908B2 (en) 2020-02-13
US20240285641A1 (en) 2024-08-29
JP7323985B2 (ja) 2023-08-09
EP3180002B1 (en) 2022-04-20
EP3180002A4 (en) 2018-07-04
US20210145839A1 (en) 2021-05-20
ES2925471T3 (es) 2022-10-18
AU2015302908A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US20240285641A1 (en) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
JP5881704B2 (ja) Ｎａｍｐｔの阻害のための新規な化合物及び組成物
JP6254169B2 (ja) ベンズアミドおよびヘテロベンズアミド化合物
JP5872027B2 (ja) ニコチンアミドホスホリボシルトランスフェラーゼ（ｎａｍｐｔ）を阻害するためのピペリジン誘導体および組成物
CA3142340A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
AU2021212003B2 (en) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
KR20090091350A (ko) 단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체
JP2017508757A (ja) スルホン基を含有する５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体
JP2016523282A (ja) スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用
KR20140014104A (ko) 치환된 이미다조퀴놀린 유도체
JP2017511325A (ja) スルホンジイミン基を含むジ置換５−フルオロピリミジン誘導体
HK1238549B (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
HK1238549A1 (en) Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
JP2007531775A (ja) 高増殖状態の処置のためのキノロンカルボン酸誘導体
HK1193813B (en) Pharmaceutically active disubstituted pyridine derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104